Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis

被引:0
|
作者
Ning, Chunhui [1 ]
Yan, Yunzi [2 ]
Wang, Yansong [2 ]
Li, Rui [1 ]
Liu, Wenjie [1 ]
Qiu, Linjie [1 ]
Sun, Lingyun [1 ]
Yang, Yufei [1 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China
[2] Beijing Univ Tradit Chinese Med, Grad Coll, Beijing, Peoples R China
基金
北京市自然科学基金;
关键词
chemotherapy induced nausea and vomiting; bibliometric analysis; research trends; hot spots; knowledge mapping analysis; ANTIEMETICS AMERICAN SOCIETY; PLACEBO-CONTROLLED TRIAL; OLANZAPINE; 5; MG; DOUBLE-BLIND; EMETOGENIC CHEMOTHERAPY; ANTAGONIST APREPITANT; CANCER-PATIENTS; BREAST-CANCER; PHASE-III; PREVENTION;
D O I
10.3389/fphar.2024.1369442
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: CINV is a frequent adverse response to cancer treatment. There is still much to learn about the pathophysiology and initiating event of CINV, which necessitates continued research despite decades of effort. Identifying the current foci of the complex disease and assessing the scientific impact of pertinent study are made more difficult by the abundance of publications on CINV. Therefore, our goals in this article are to evaluate developments in this field, examine patterns in research domains, and gauge the expansion of CINV research production globally. Methods: Articles about CINV published between 2012 and 2022 were found by searching the Web of Science Core Collection of Clarivate Analytics. The number of publications over time was visualized using Microsoft Office Excel 2019. CiteSpace and VOSviewer were utilized to create knowledge maps that analyzed collaborations between nations, organizations, and writers. They also presented the history of CINV research and highlighted its current areas of focus. Results: In this study, 846 papers in all were assessed. Most publications (237, 28.01%) came from the United States. University of Toronto was the most productive institution (34, 4.01%). With 25 articles published, or 2.96% of the total, Aapro Matti published the most. The most frequently published journal was found to be Supportive Care (158, 18.68%). "Palonosetron," "Moderately emetogenic chemotherapy," "5-HT3 receptor antagonist," and "Neurokinin 1 receptor antagonists" were considered the hot topics. It can be seen that the research focus is on the drug treatment of chemotherapy-induced nausea and vomiting. Conclusion: Through bibliometric analysis, we were able to gain profound insights into CINV research for the first time. Researchers looking to uncover research frontiers and comprehend important information in this discipline may find the study's findings useful.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis
    Jin, Yan
    Wu, Xiaomin
    Guan, Yanmeng
    Gu, Dongying
    Shen, Yue
    Xu, Zhi
    Wei, Xiaowei
    Chen, Jinfei
    SUPPORTIVE CARE IN CANCER, 2012, 20 (08) : 1815 - 1822
  • [22] Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
    Timaeus, Sarah
    Elder, Joshua
    Franco, Kyle
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (07) : 527 - 531
  • [23] Evaluating Chemotherapy-induced Nausea and Vomiting and Food Intake in Patients With Gynecologic Cancer
    Komatsu, Hiroaki
    Oishi, Tetsuro
    Sato, Shinya
    Osaku, Daiken
    Sawada, Mayumi
    Kudoh, Akiko
    Nonaka, Michiko
    Sato, Seiya
    Shimada, Muneaki
    Itamochi, Hiroaki
    Harada, Tasuku
    ANTICANCER RESEARCH, 2019, 39 (08) : 4555 - 4560
  • [24] Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity
    Vig, Sierra
    Seibert, Laurel
    Green, Myke R.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (01) : 77 - 82
  • [25] Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network
    Hori, Katsuhito
    Kobayashi, Norihiro
    Atsumi, Hitoshi
    Nagayama, Akira
    Kondoh, Masako
    Noge, Ichiro
    Kimura, Midori
    Utsugi, Hiroaki
    Iwasaki, Tsuyoshi
    Nakamura, Masaki
    Kimura, Tomomi
    SUPPORTIVE CARE IN CANCER, 2014, 22 (04) : 969 - 977
  • [26] Patient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
    Grunberg, Steven
    CANCER CONTROL, 2012, 19 (02) : 10 - 15
  • [27] New options and controversies in the management of chemotherapy-induced nausea and vomiting
    Koth, Sara M.
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (11) : 812 - 819
  • [28] ROLAPITANT HYDROCHLORIDE: PROPHYLACTIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
    Navari, R.
    DRUGS OF TODAY, 2016, 52 (08) : 431 - 438
  • [29] Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting
    Ruhlmann, Christina H.
    Herrstedt, Jorn
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 139 - 150
  • [30] Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant
    Sankhala, Kamalesh K.
    Pandya, Devesh M.
    Sarantopoulos, John
    Soefje, Scott A.
    Giles, Francis J.
    Chawla, Sant P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (12) : 1607 - 1614